|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
381,510,000 |
Market
Cap: |
169.20(M) |
Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,697 |
52
Week Range: |
$0.4435 - $2.04 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
500,000 |
525,000 |
525,000 |
Total Buy Value |
$0 |
$324,050 |
$343,050 |
$343,050 |
Total People Bought |
0 |
1 |
2 |
2 |
Total Buy Transactions |
0 |
1 |
2 |
2 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Klaskin Christine M |
VP Finance |
|
2012-06-20 |
4 |
D |
$4.99 |
$18,194 |
D/D |
(3,646) |
24,590 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2012-06-20 |
4 |
D |
$4.92 |
$77,702 |
D/D |
(15,793) |
589,709 |
|
- |
|
Klaskin Christine M |
VP Finance |
|
2012-06-19 |
4/A |
A |
$5.26 |
$39,219 |
D/D |
7,456 |
28,236 |
|
- |
|
Wentworth Kerry |
VP, Clinical, Reg, & Quality |
|
2012-06-19 |
4 |
A |
$5.26 |
$74,445 |
D/D |
14,153 |
59,218 |
|
- |
|
Sharp Shalini |
Director |
|
2012-06-19 |
4 |
A |
$5.26 |
$66,870 |
D/D |
12,713 |
82,590 |
|
- |
|
Klaskin Christine M |
VP Finance |
|
2012-06-19 |
4 |
A |
$5.26 |
$109,303 |
D/D |
20,780 |
28,236 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2012-06-19 |
4 |
A |
$5.26 |
$482,126 |
D/D |
91,659 |
605,502 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2012-06-01 |
4 |
A |
$5.71 |
$13,198 |
D/D |
2,310 |
513,843 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2012-05-01 |
4 |
A |
$6.42 |
$13,198 |
D/D |
2,057 |
511,533 |
|
- |
|
Valentine Karen |
VP General Counsel |
|
2012-04-26 |
4 |
A |
$6.43 |
$2,681 |
D/D |
417 |
20,137 |
|
- |
|
Wentworth Kerry |
VP, Clinical, Reg, & Quality |
|
2012-04-26 |
4 |
A |
$6.43 |
$4,469 |
D/D |
695 |
45,065 |
|
- |
|
Sharp Shalini |
CFO |
|
2012-04-26 |
4 |
A |
$6.43 |
$4,019 |
D/D |
625 |
69,877 |
|
- |
|
Klaskin Christine M |
VP, Finance |
|
2012-04-26 |
4 |
A |
$6.43 |
$2,681 |
D/D |
417 |
20,780 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2012-04-26 |
4 |
A |
$6.43 |
$8,931 |
D/D |
1,389 |
509,476 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2012-04-02 |
4 |
A |
$5.15 |
$357,412 |
D/D |
51,457 |
508,087 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2012-03-30 |
4 |
D |
$6.60 |
$3,300,000 |
D/D |
(500,000) |
456,630 |
|
- |
|
Wentworth Kerry |
VP, Clinical, Reg, & Quality |
|
2012-03-15 |
4 |
A |
$5.31 |
$32,269 |
D/D |
6,077 |
44,370 |
|
- |
|
Sharp Shalini |
CFO |
|
2012-03-15 |
4 |
A |
$5.31 |
$25,817 |
D/D |
4,862 |
69,252 |
|
- |
|
Valentine Karen |
VP, General Counsel |
|
2012-03-15 |
4 |
A |
$5.31 |
$15,420 |
D/D |
2,904 |
19,720 |
|
- |
|
Klaskin Christine M |
VP, Finance |
|
2012-03-15 |
4 |
A |
$5.31 |
$10,620 |
D/D |
2,000 |
20,363 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2012-03-15 |
4 |
A |
$5.31 |
$71,186 |
D/D |
13,406 |
956,630 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2012-03-01 |
4 |
A |
$3.14 |
$13,198 |
D/D |
4,204 |
943,224 |
|
- |
|
Armen Garo H |
chairman & CEO |
|
2012-02-01 |
4 |
A |
$2.47 |
$13,198 |
D/D |
5,339 |
939,020 |
|
- |
|
Wentworth Kerry |
VP, Clinical, Reg, & Quality |
|
2012-01-26 |
4 |
A |
$2.76 |
$1,915 |
D/D |
694 |
38,293 |
|
- |
|
Valentine Karen |
VP, General Counsel |
|
2012-01-26 |
4 |
A |
$2.76 |
$1,151 |
D/D |
417 |
16,816 |
|
- |
|
536 Records found
|
|
Page 11 of 22 |
|
|